T2005010
Triflusal Unreinheit B
European Pharmacopoeia (EP) Reference Standard
Synonym(e):
2-Hydroxy-4-(trifluormethyl)-benzoesäure, 4-(Trifluormethyl)-salicylsäure
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C8H5F3O3
CAS-Nummer:
Molekulargewicht:
206.12
UNSPSC-Code:
41116107
NACRES:
NA.24
Empfohlene Produkte
Qualität
pharmaceutical primary standard
API-Familie
triflusal
Hersteller/Markenname
EDQM
Anwendung(en)
pharmaceutical (small molecule)
Format
neat
Lagertemp.
2-8°C
InChI
1S/C8H5F3O3/c9-8(10,11)4-1-2-5(7(13)14)6(12)3-4/h1-3,12H,(H,13,14)
InChIKey
XMLFPUBZFSJWCN-UHFFFAOYSA-N
Allgemeine Beschreibung
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Anwendung
Triflusal impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Verpackung
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Sonstige Hinweise
Sales restrictions may apply.
Hier finden Sie alle aktuellen Versionen:
Analysenzertifikate (COA)
Lot/Batch Number
Leider sind derzeit keine COAs für dieses Produkt online verfügbar.
Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
C Velasco et al.
The Journal of urology, 166(5), 1962-1968 (2001-10-05)
We examined the effects of intravenous administration of the 2 nuclear factor-kappaB inhibitors aspirin and 2-hydroxy-4-trifluoromethylbenzoic acid (HTB) on bladder filling and voiding in anesthetized and conscious rats. Disappearance of isovolumic bladder contractions after intravenous administration of different doses of
R Mis et al.
European journal of clinical pharmacology, 42(2), 175-179 (1992-01-01)
2-hydroxy-4-trifluoromethylbenzoic acid (HTB) is the main active metabolite of the platelet antiaggregant drug triflusal. Its binding to plasma proteins of rats and healthy volunteers in vitro and in vivo has been studied. Rats were given a single oral dose of
Hea-Young Cho et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 798(2), 257-264 (2003-12-04)
A rapid, selective and sensitive high-performance liquid chromatography (HPLC) method was developed and validated for the simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid (HTB), in rat and human plasma. HPLC analysis was carried out using
M Valle et al.
European journal of clinical pharmacology, 61(2), 103-111 (2005-02-16)
Triflusal has been shown to exert neuroprotective effects by downregulating molecules considered responsible for the development of Alzheimer's disease (AD). The aim of this study was to develop a population pharmacokinetic model to characterize plasma and cerebrospinal fluid (CSF) pharmacokinetics
J Ramis et al.
International journal of clinical pharmacology, therapy, and toxicology, 28(8), 344-349 (1990-08-01)
Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.